HBV reactivation in patients with rheumatoid arthritis treated with anti-interleukin-6: a systematic review and meta-analysis
Authors' conclusion
Overall, anti-IL-6 treatment comes with a significant risk of HBVr in RA patients with CHB; risk is diminished when antiviral prophylaxis is used. In contrast, in RA patients with resolved HBV infection, the risk of HBVr seems to be extremely low.
Study context
- Population
- RA patients with chronic or resolved HBV infection under anti-IL-6 treatment; PubMed, Scopus and EMBASE searched, last updated 28 January 202319 articles
- Participants
- 372 patients
- Comparison
- Chronic HBV (CHB) vs CHB, no antiviral prophylaxis vs Resolved HBV infection
- Outcome
- HBV reactivation (HBVr)
Pooled result
As reported in the abstract
HBVr risk
Further pooled results
Management of HBV reactivation (HBVr)
- All RA patients experiencing HBVr were successfully managed with antiviral treatment and/or drug withdrawal
Original publication
HBV reactivation in patients with rheumatoid arthritis treated with anti-interleukin-6: a systematic review and meta-analysis. Rheumatology (Oxford). Published 23 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →